In the field of medicine nanotechnology may help to develop new and effective applications. However, as with many modern technologies, there are considerable moral, legal and social concerns about the consequences nanotechnology may have for humans and their environment. More than in many other areas of nanotechnology, nanomedicine stimulates stakeholders to raise concerns. Not only are patients concerned, but so are those in politics and administration, in industry and in the scientific community there are substantial debates about ethical, legal, and social implications (ELSI) of nanomedicine.
Nanotechnology is widely thought to be a key technology of the 21st century. Especially in the field of medicine nanotechnology may help to develop new and effective applications. However, like many modern technologies, there are considerable concerns about the consequences nanotechnology may have for us and our environment. Especially nanomedicine raises concerns. Not only are patients concerned, but also in politics and administration, in industry and in the scientific community there are substantial debates about desired and undesired consequences of nanomedicine. Though clearly ethical, legal, and social implications (ELSI) of nanomedicine involve not only the natural sciences and medicine, but other disciplines such as moral philosophy and law too, it seems that an integrated, interdisciplinary cooperation on ELSI issues of nanomedicine is rarely practiced. (Notable exceptions have been the EC funded projects Nano2Life and observatoryNANO.) A recent example of an EU funded consortium where an ELSI discourse has been integral part of the consortium's design and working program is the NanoDiaRA project. 1 Here we report on the consortium's conference "Nanomedicine: Visions, Risk, Potential", that took place at the Berlin-Brandenburg Academy of Sciences, from 19 to 20 April 2012, and brought together about 50 participants from various disciplines such as medicine, the natural sciences, moral philosophy, law, and the social sciences (Table 1) . Additionally, the conference included a poster competition on ELSI issues of nanomedicine.
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The speakers at the conference's first session outlined the current state of the art of nanomedicine. From the beginning it became clear that utopian and dystopian views on the future of nanotechnology and nanomedicine, where, for example, nanosized machines autonomously travel inside the human body to perform their tasks, lack a sound scientific basis. Though technology visions may have a function in shaping technology development, dealing with concerns about nanomedicine should be based on a realistic view of the potential of nanotechnology. Exaggerating the consequences of nanotechnology is a strategy frequently adopted by supporters as well as critics of nanotechnology. Besides being a more or less successful strategy for supporting one's (pro or con) interests, it turns into a moral problem, when this exaggeration blurs a clear view on chances and risks of nanotechnology thereby hampering rational public debate.
The first speaker, Professor Hofmann (Ecole Polytechnique Fédérale de Lausanne, Institute of Materials Properties), gave an introduction to nanoparticles (NPs), focusing on using NPs in imaging procedures for the early diagnosis of rheumatoid arthritis and osteoarthritis. For that matter he drew on preliminary results of the already mentioned EU-funded research consortium NanoDiaRA. NanoDiaRA combines a nanoparticle based approach as a generic platform for the development of various novel diagnostic technologies. Effective treatments in rheumatoid arthritis and osteoarthritis are based on the early detection of the disease and monitoring of the treatment efficacy. In detail, nanoparticle-based diagnosis includes microarray and imaging technologies detecting disease-related molecular and cellular processes with high sensitivity and specificity. These new therapeutic approaches have potentials for daily clinical use. Next to this very specific application, Prof. Hofmann outlined the general possibilities of applying bio-active magnetic NPs and quantum dots for medical applications. They can be widely used in therapy and diagnosis. Professor Hofmann also used the example of NanoDiaRA for illustrating a successful interdisciplinary collaboration: Biomedical research can elucidate the molecular characteristics of biomolecules involved in joint inflammation. Based on this information, it is possible to develop NPs that specifically interact with these biomolecules and thereby enable a sensitive and site-specific visualization of the inflammation. In the second part of his talk, Hofmann gave an overview on several applications of NPs that are either approved and in clinical use already, e.g., MRI applications for liver diagnostic, or that are at the stage of pre-clinical and clinical tests. The multifunctional particles used for these applications have an approved biocompatibility and allow active diagnosis and therapeutic methods. Synthesis and surface modification of these particles are well established in the industrial scale and offer a useful toolbox for "theranostics", a treatment strategy combining diagnostics with therapeutics. Promising as these approaches are, there remain considerable uncertainties. It is not known in detail, for example, how NPs distribute in the human body and what their long-term fate is. Equally the interaction of NPs with proteins is still not fully understood.
In the second talk, Professor Müller (Free University of Berlin, Institute of Pharmacy) presented the possibilities for drug delivery with nanoscaled organic capsules and containers as an example for therapeutic applications. He gave an overview of the history of nanoscaled carriers, in particular nanoemulsions, microemulsions, polymeric and lipid NPs and nanocrystals used as carriers for drugs. Nanocarriers can have a variety of functions, such as enhancing the bioavailability for poorly soluble drugs, optimizing drug release or reducing side effects. Their basic structure comprises two elements: a "shell" that provides the surface of the particle with certain desired properties (e.g., making it hydrophilic, trigger interactions with specific cell types, etc.) and a "core" that enables the take-up of drugs and other compounds that need to be transported to the desired location. Müller's talk showed that a large range of nanotechnology-based pharma products is on the market. However, up to now they mainly enable controlled release but not specific targeting of the therapeutic compounds they carry. Another focus of this talk was the insufficient toxicological characterization of nanoscaled compounds. Prof. Müller suggested a Nanotoxicological classification system (NCS) derived from a Matrix made up from size and persistency. Particles above 100 nm are less problematic than smaller ones since they are not undergoing endocytosis in an organism. Biodegradable particles are less problematic Prof. Harro van Lente (University of Utrecht, Netherlands) "Nanomedicine is more than a matter of risk. The generic tendency to focus on public acceptance and risk perception" 8 Dr. Joscha Wullweber (University of Kassel, Germany) "Nanotechnology and society" 9
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than non-biodegradable ones. This leads to four classes: class I (size above 100 nm, biodegradable); class II (size above 100 nm, non-biodegradable); class III (size below 100 nm, biodegradable); class IV (size below 100 nm, non-biodegradable). In the interpretation of Müller class I particles (biodegradable, above 100 nm) are the rather un-complicated and the class IV particles (non-biodegradable, below 100 nm) are the most problematic ones. As a reply on the suggestion of the NCS Matrix, some discussants pointed out that from his point of view such a system is problematic since it gives the impression of simplicity where actually complexity is the case. The first two lectures were followed by a controversial discussion on the proper definition of "nano-structures" -mere size-related definitions were widely judged as less satisfactorily as other definitions focusing on novel chemical and physical properties due to the small size of the particles. In that case some of the particles mentioned by Prof. Müller might not deserve the name "nanoparticle" as their effect is not actually achieved by a "nanosize-effect" but by supramolecular interactions. Also, some nanotechnologists doubted that particles above 100 nm should be called NPs at all. Liposomes and vesicles usually form a mixture of objects of a size up to 500 nm and have certainly no nanosize-effect at that dimension. Moreover, the majority view was that only those nanosized compounds should be defined as NPs that are the product of a technical process. Such engineered NPs should be differentiated from natural and biological NPs such as fine dust, proteins and viruses. From the ethical point of view, it is important to note that the plea for precise terminology is not only a plea for precise technical or scientific terms. Moral discourse, too is reliant on clear language. Indeed many controversies in bioethical debates are aggravated by using decisive terms in an unclear manner.
In his talk, Dr. Jordan (MagForce AG) gave a case study on brain-cancer therapy by hyperthermia using NPs. This therapy is based on the introduction of magnetic, ironoxide NPs into the tumor, and their ability to convert magnetic energy into therapeutic heat. Following particle-injection into the tumor, a magnetic field that changes its polarity 100,000 times per second is applied whereby the NPs are activated and emit heat. Depending on the duration of treatment and the intratumoral temperatures achieved, the tumor cells are either directly destroyed (thermal ablation) or sensitized for concomitant chemo or radiotherapy (hyperthermia). The treatment sheme developed by Dr. Jordan has been successfully carried out on 600 patients (April 2012). Jordan gave detailed and valuable insight into the process of scientific development, industrial upscaling and marketing and described the obstacles he and his collaborators had to overcome along this way. Whereas so far nanotechnological materials underwent the classification regulations of chemicals, nanosized medical compounds are subject to drug classification -a procedure that takes a much longer time. In case of MagForce's NPs for hyperthermia it was, as it seems, the company's luck that they were regarded as a "device" and not a "compound". This mere decision reduced the required testing phase from 5 to 2 years.
Jordan's talk and the following debate made clear, that there is a need for improved guidelines enabling transparent evaluation and certification procedures for nanomedical substances. Such guidelines would have to take into account and to balance the various interests tied to the development of new nanomedical procedures -be the interest medical, economic, or ethical and legal. These regulations should also reflect that the ultimate goal of nanomedical products is to improve patient care.
In the last talk of the fist session Dr. Ciofani (Scuola Superiore Sant'Anna, Istituto Italiano di Tecnologia) described the nanomedical application of boron nitride nanotubes (BNNT), barium titanate NPs and zink oxide NPs as possible materials for NPs. BNNTs are of significant interest because of their piezoelectric properties that can be exploited for cell stimulation. Applications of BNNTs in the biomedical field range from drug delivery systems, boron carriers for boron neutron capture therapy to cellular nanotransducers. This talk illustrated the challenges of nanomedicine in the next future, exploiting the rapid advances in nanomaterials beyond the well-established organic and inorganic NPs of today for biomedical applications. The co-operation of different disciplines such as bioengineering, materials science, chemistry, physics, biology, as well as medicine, will prove to be essential for the successful exploration of the applications of nanomaterials inside cells, and for effective and realistic applications in clinical practice.
Over and above introducing the rapidly evolving research in nanomedicine, already the first session made clear that nano-technology in general, but also nanomedicine its driven by far more than "pure" scientific interest. The prospects of therapeutic benefits, but also the pursuit of economic success and political programs makes research and development in nanomedicine a complex issue neither easily described nor easily regulated. The balancing of these various interests is in itself not a scientific or descriptive process. Rather it involves normative considerations on the relative importance of, e.g., economic interests as compared to the availability of new medical applications. Technology assessment of nanotechnology should take into account such normative dimensions too.
The question of risk, one of the most debated issues among the possible adverse consequences of nanomedicine, was discussed during the second session. From Professor Krug's talk (EMPA, Department "Materials meet Life"), an expert on toxicology, one got the impression that with the currently available methods the reliability of toxicological datasets of nanomaterials is not satisfactory. Although the number of publications on "nanotoxicology" increased massively in the past years, there is still no systematic picture of risks related to NPs available. The huge amount of new chemicals and expected new nanomaterials on the market raises the question for alternative methods for screening. It seems that many of the methods used are not adapted for NPs and thus results are often false-positive or false-negative. It could be demonstrated that the interference of NP with the assay systems often is neglected, solvent problems have not been addressed and the appropriate controls as well as the characterization of the materials tested were missing. Taking all these critical points into account a new nanotoxicological strategy should be established in the future. Drawing on Prof. Krug's research it seems recommendable to verify cytotoxicity with at least two or more independent test systems for this new class of materials (nanomaterials). Moreover, for standardizing nanotoxicological assays reference materials are needed. Several international research projects (DaNa, NanoSafety, NanoTrust, and others) and institutes (i.e., SafeNano, Centre for NanoSafety, and others) work on recommendations which should lead to more detailed and reliable information about the biological activity of specific nanomaterials. Especially the in vitro methods should be reliable, robust, sensitive and predictive. Prof. Krug pleads for a continuous support of (nano)toxicological activities and projects as risk characterization and assessment are crucial for a responsible process of marketing "nanotechnologies" within the next decade. The most urgent goal is the comparability of tox-studies that could be achieved by the use of standardized methods, reference materials and the appropriate controls in each experimental set-up. Harmonization of testing strategies and methods has to be achieved very quickly as otherwise the confusion about the results published will increase the uncertainty and the proper use of nanomaterials in all fields of interest. In summary, the talk left the impression that current toxicological findings are of limited reliability only, and that today not enough is known about the effects of nanomaterials on organisms. Researchers tend to see the issue of risk and uncertainty as a scientific one only, and surely this is the approach of choice if the aim is to collect reliable knowledge on possible negative side effect of nanosubstances. But the risk debate, especially in the public sphere, has more facets, e.g., the issue of risk-perception and -communication. Without going into details here, it is worth considering the argument that the ongoing controversies on Genetically Modified Organisms, are only partly about adequate (scientific) risk-assessment. Overlapping are issues of suitable risk-communication as well as specific risk-perception in the general public. With respect to public acceptance of nanotechnology one should bear in mind, therefore, that the issue of "risk" has several dimensions relevant for understanding public attitudes towards nanotechnology. If shaping public discourse on risks of new technologies is to be more than teaching an allegedly uniformed public about "objective" risk-levels, then the complex cultural mechanisms of dealing with risks should be respected and taken into consideration.
Joel D'Silva (University of Twente, Department of Legal and Economic Governance Studies) analyzed in his talk the European Commission's policy on nanotechnology and compared it to other regulations on the national and international level. While the potential benefits of nanomedicine appear to be enormous, concerns about the adequacy of regulatory oversight also threaten to impede the development and commercialization of nanomedicine-based products. It is becoming increasingly clear, therefore, that appropriate and effective regulatory structures will be fundamental to the successful implementation and commercialization of nanomedicine. Up to now there are neither specific nanomedical laws in the European Union, nor indeed in any other jurisdiction. But this does not mean that nanomedicine is "unregulated". Rather, such products are regulated in the same way as their non-nanotechnology counterparts, with existing legislation on medicinal products and devices, tissue engineering and other advanced therapies being applicable to nanomedicine-based products and processes. In particular, the current framework relevant for nanomedicine Specific directives for biological products and medical devices also play a role. D'Silva also pointed out the importance of proper definitions for nanomaterials-a complex and contested task seen as much as a political endeavor as it is a scientific one. It might be even necessary to define nanomaterials differently for regulatory purposes than for other classificatory purposes. Another aspect he addressed is the role of public participation in regulatory strategies and the conceptual and practical difficulties that go along with that (defining who are the public, the degree and extent of participation, related public concerns and values, which are not easy to discern or measure as the public is not a homogenous group). The most important messages from his talk were, that regulatory difficulties occur from insufficient scientific data, that current quality systems and published product standards are not suitable to address concerns relating to nanotechnology, and that there is an urgent need to identify and address social, health and environmental risks posed by nanomedicine.
The third session entitled "Science, industry and the public" outlined the social and ethical dimensions of nanomedicine. Professor van Lente (University of Utrecht, Department of Innovation and Environmental Studies) investigated the field of nanotechnology and nanomedicine from the perspective of the political sciences. He argued that the further development of the field should be accompanied by a proper social embedding, i.e., the engagement of the general public. The central argument of his talk was that there is commonly a double misperception when it comes to the debate of societal embedding in large R&D agendas such as EU framework programs: the question of societal embedding is first reduced to a problem of public acceptance and then this is reduced to a matter of risk perception. Societal embedding, however, is more than public acceptance. It refers to broader questions about the way economic structures are re-organized, about changing responsibilities and liabilities, about new roles and identities, about new ethical dilemmas. Furthermore, even though public acceptance depends to a certain extent on risk perceptions, there are other concerns including, e.g., moral and political views on the naturalness of new technologies, or matters of justice related to access to new technologies. According to van Lente, this broader view of the social embedding of nanotechnology should be taken into account on a political level by further activities to include "ELSI" projects into research programs and in industry by "HSE" (health, safety and environment) standards which go deeper than mere risk assessment.
In his talk Dr. Wullweber (University of Kassel, Department of Political Science) characterized nanotechnology rather not as a research area driven by scientific progress and promising applications, but more as a "political project" based on the interest to push high-technology through political and media campaigns. This political agenda is, according to Wullweber, the main reason that nanotechnology is currently more accepted than, e.g., genetic engineering, although these two fields of research had many similarities in the public perception. Whether new technologies can prevail as products and applications strongly depends on their degree of acceptance in society. But Wullweber added a slightly different viewpoint: In view of the recent discourse surrounding nanotechnology it is no surprise that attitudes towards nanotechnology to date have tended to be positive. In no small measure this development is the result of successful discourse strategies in that a lot of effort is invested in order to create a positive atmosphere. Dr. Wullweber's talk caused a controversial discussion. Whereas many in the audience agreed with Prof. van Lente on his plea for societal embedding, Wullweber's view of nanotechnology as a largely political program generated passionate resistance.
In the final talk, Professor Brownsword (King's College, Research Centre TELOS) called for a specific regulatory regime for nanomedicine. Such governance approach should focus on (1) improving data gathering and sharing in the face of limited resources; (2) filling newly exposed or created regulatory gaps; (3) incentivizing strong corporate stewardship beyond regulatory requirements; (4) enhancing agency expertise and coordination; (5) providing for regulatory adaptability and flexibility; and, (6) achieving substantial, diverse stakeholder involvement. The result of these proposals would be a system that is more protective of human health and the environment, more efficient for industry and taxpayers, and better geared for responsible technology development. In Brownsword's view, nanomedicine does present serious regulatory challenges, however, there is no need to make exceptional provision as the regulatory resources to handle nanomedicine are available. Furthermore, Brownsword argued that "informed consent" cannot serve alone as the central normative principle that governs the nanomedical relationship between doctors and patients, as it remains unclear how consent can be informed when there is considerable uncertainty on the actual risks and benefits of nanomedical methods. It should rather be the responsibility of regulators to ensure that in clinical practice individuals are in a position to make their own informed self-interested choices only above a previously determined safety threshold.
The lively and somewhat controversial debates during the conference showed that though nanomedicine surely bears great potential to improve clinical medicine, the advantage of these new approaches as compared to conventional methods has still to be proven. Especially the adequate risk determination of nanomedical methods remains a critical issue for the further development of nanomedicine. The conference also made clear that the issue of risk is not exhausted by establishing a suitable scientific methodology of risk assessment. Though without doubt such methodology is desirable, it will not alone settle the public concerns with nanotechnology. One reason for that is that the way risk is communicated to and perceived by the general public is influencing the way new technologies are assessed outside academic circles. Reducing risk to a scientific, purely empirical issue will likely be insufficient for understanding and guiding the public's concerns with nanotechnology.
Another point of moral relevance is that nanotechnology in general as well as in nanomedicine in particular is a field of research laden with scientific/medical hopes and promises as well as with economic and political interests. Thereby, the moral evaluation of nanotechnology must take into account this complex web of different factors influencing the future development of this fascinating field of research.
